Sulfaphenazole (C4131): Precision CYP2C9 Inhibition and Translational Research Utility

Executive Summary: Sulfaphenazole (CAS No. 526-08-9) is a potent, selective, and competitive inhibitor of cytochrome P450 enzymes CYP2C6 and CYP2C9, displaying an IC₅₀ of 0.63 μM for CYP2C9 at 37°C in vitro (Chen et al., 2021). It disrupts folic acid synthesis in bacteria via dihydropteroate synthase (DHPS) inhibition, conferring antibacterial activity against Mycobacterium tuberculosis, including XDR-TB. Sulfaphenazole demonstrates low cytotoxicity (IC₅₀ >64 μg/mL, Vero cells), high solubility in DMSO (≥13.15 mg/mL), and proven efficacy in vascular function restoration and oxidative stress reduction in rodent models (APExBIO). Its pharmacological profile supports use in drug metabolism modulation, vascular endothelial function research, and anti-tuberculosis assays.

Biological Rationale

Sulfaphenazole is a 4-aminobenzenesulfonamide compound. It serves as both a selective CYP2C9 inhibitor and an antibacterial agent. The compound targets bacterial DHPS, an enzyme critical for folic acid biosynthesis, and cytochrome P450 2C9, a key enzyme in human drug metabolism (Chen et al., 2021). CYP2C9 is responsible for metabolizing approximately 15–20% of clinically used drugs, including anticoagulants and antidiabetics. Inhibiting this enzyme enables studies of drug-drug interactions, pharmacogenetics, and adverse drug reactions. Sulfaphenazole's selectivity allows for precise dissection of CYP2C9-mediated pathways without significant off-target inhibition of other CYP isoforms. Its antibacterial mechanism is relevant for combating multidrug-resistant and extensively drug-resistant tuberculosis. The molecule’s dual utility in both microbiology and pharmacology research underlines its translational value.

Mechanism of Action of Sulfaphenazole

Sulfaphenazole competitively inhibits CYP2C9 and CYP2C6 by binding to their active sites, thereby blocking substrate access. The IC₅₀ value for CYP2C9 inhibition is 0.63 μM under standard in vitro conditions (pH 7.4, 37°C) (Chen et al., 2021). This inhibition reduces oxidative stress in endothelial cells by suppressing CYP2C-mediated reactive oxygen species formation. In bacterial systems, Sulfaphenazole inhibits DHPS, a key enzyme in the folic acid pathway, resulting in impaired DNA synthesis and bacteriostasis. The antibacterial effect is particularly pronounced against Mycobacterium tuberculosis, including XDR-TB strains. Sulfaphenazole’s dual mechanism—CYP2C9 inhibition in mammalian systems and DHPS inhibition in bacteria—enables cross-disciplinary research applications.

Evidence & Benchmarks

• Sulfaphenazole inhibits human CYP2C9 with an IC₅₀ of 0.63 μM at 37°C in recombinant enzyme assays (Chen et al., 2021).
• In vitro, Sulfaphenazole demonstrates MIC values of 5–30 μg/mL against M. tuberculosis H37Rv, including drug-resistant strains (Chen et al., 2021).
• Cytotoxicity assays on Vero cells show an IC₅₀ >64 μg/mL, indicating a favorable safety profile (Table 2).
• Daily intraperitoneal injection of 5.13 mg/kg improved vascular function in diabetic mouse models by restoring endothelium-dependent vasodilation (APExBIO).
• Sulfaphenazole enhances wound healing in pressure- and thermal-injury models by reducing inflammation and fibrosis, and increasing macrophage bactericidal activity (internal article).
• Compound remains stable for at least several days at -20°C and is soluble in DMSO (≥13.15 mg/mL) and ethanol (≥9.92 mg/mL, with ultrasonic assistance) (APExBIO).

This article updates and extends findings presented in "Sulfaphenazole and Precision CYP2C9 Inhibition in Vascula..." by offering quantitative cytotoxicity and anti-TB benchmarks, and clarifies translational modeling utility compared to "Sulfaphenazole: Precision CYP2C9 Inhibitor for Vascular..." by detailing dose ranges and comparative selectivity.

Applications, Limits & Misconceptions

Sulfaphenazole’s primary applications include:

• Selective inhibition of CYP2C9 and CYP2C6 for drug metabolism and pharmacogenetics research.
• Dissecting CYP2C-mediated oxidative stress pathways in vascular and metabolic disease models.
• Studying antibacterial activity against M. tuberculosis, including XDR-TB, via DHPS inhibition.
• Elucidating adverse drug reaction mechanisms in preclinical models.
• Facilitating wound healing research in pressure and thermal injury models.

Compared with other CYP2C9 inhibitors, Sulfaphenazole (C4131, APExBIO) exhibits high selectivity, low cytotoxicity, and robust solubility parameters, enabling reproducible results in both cell-based and animal assays (internal article).

Common Pitfalls or Misconceptions

• Not a pan-CYP inhibitor: Sulfaphenazole is selective for CYP2C9 and CYP2C6, with minimal inhibition of other CYP isoforms (Chen et al., 2021).
• Limited water solubility: Compound is insoluble in water; proper dissolution in DMSO or ethanol is required for assay accuracy (APExBIO).
• Short-term solution stability: Sulfaphenazole solutions are stable for only a few days at -20°C and should be freshly prepared (APExBIO).
• Not suitable for all bacterial species: Demonstrated activity is primarily against M. tuberculosis, not all gram-negative/positive bacteria (Chen et al., 2021).
• Potential for drug-drug interactions: High CYP2C9 inhibition may confound studies involving substrates of this enzyme (Chen et al., 2021).

Workflow Integration & Parameters

For CYP2C9 inhibition assays, typical Sulfaphenazole concentrations range from 0.5 to 11.5 μM. For anti-tuberculosis studies, 5–30 μg/mL is recommended. Cell function assays employ 1–10 μM. In animal models, daily intraperitoneal doses of 5.13 mg/kg have been used to restore vascular function in diabetic mice. Compound stock solutions are prepared in DMSO (≥13.15 mg/mL) or ethanol (≥9.92 mg/mL, with ultrasonic assistance). Solutions should be stored at -20°C and used within several days for best stability. APExBIO’s Sulfaphenazole (C4131) is supplied as a high-purity powder, facilitating reproducible experimental outcomes (APExBIO).

Conclusion & Outlook

Sulfaphenazole (C4131, APExBIO) remains the gold standard for selective, competitive CYP2C9 inhibition in both in vitro and in vivo research. Its unique dual action as a CYP2C inhibitor and antibacterial agent against M. tuberculosis enables advanced pharmacogenetics, drug metabolism modulation, and translational vascular studies. Ongoing optimization of related sulfonamides may further reduce unwanted CYP activity while retaining antibacterial potency (Chen et al., 2021). For authoritative product specifications and protocols, refer to the Sulfaphenazole product page.